Unknown PHASE2 INTERVENTIONAL 1-arm NCT05310331

Donafenib for Recurrent Cervical Cancer

Efficacy and Safety of Donafenib Combined With Paclitaxel and Platinum in Patients With Recurrent, Metastatic, and Persistent Advanced Cervical Cancer: A Single-arm, Phase II Study

Sponsor: Lei Li

Conditions Adverse Effect Chemotherapy Metastatic Cervical Carcinoma Persistent Advanced Cervical Carcinoma Recurrent Cervical Carcinoma Survival Outcomes Targeted Therapy

Interventions Donafenib combined with paclitaxel and platinum ± PD-1 antibody

Updated 3 times since 2022 Last updated: Mar 26, 2022 Started: Mar 27, 2022 Primary completion: Dec 27, 2023 Completion: Jun 27, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Adverse Effect and Chemotherapy, this trial is ongoing. The trial is conducted by Lei Li and has accumulated 3 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
May 2022 — Jul 2024 [monthly]

Recruiting PHASE2

First recorded

Mar 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Lei Li

Data source: Peking Union Medical College Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China